Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

Diamond, Lisa E.; Earle, Dennis; Rosen, Raymond C.; Willett, Michael S.; Molinoff, Perry B.

doi:10.1038/sj.ijir.3901139

Cited by 114 publications

(68 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An intranasal formulation of the drug has been developed, and the results of Phase 1 and 2A studies in normal volunteers and patients with mild or moderate ED have been reported. 15 The current studies were designed to evaluate the erectogenic potential of subcutaneously (s.c.) administered PT-141 in normal healthy volunteers and in patients with moderate or severe ED who report an inadequate response to Viagra s .…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®

Rosen¹,

Diamond

Earle

et al. 2004

Int J Impot Res

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®

Rosen¹,

Diamond

Earle

et al. 2004

Int J Impot Res

Self Cite

View full text Add to dashboard Cite

“…(Table 3 ) Given these discouraging results, Mc4 receptor agonists are currently not being developed for the treatment of obesity. However, they are being explored for other conditions such as sexual dysfunction [64]. Melanocortin antagonists are also being evaluated for the treatment of cachexia [65,66].…”

Section: Novel Targets and Drug Candidatesmentioning

confidence: 99%

Obesity Pharmacotherapy: Current Perspectives and Future Directions

Misra

2013

Current Cardiology Reviews

View full text Add to dashboard Cite

The rising tide of obesity and its related disorders is one of the most pressing health concerns worldwide, yet existing medicines to combat the problem are disappointingly limited in number and effectiveness. Recent advances in mechanistic insights into the neuroendocrine regulation of body weight have revealed an expanding list of molecular targets for novel, rationally designed antiobesity pharmaceutical agents. Antiobesity drugs act via any of four mechanisms: 1) decreasing energy intake, 2) increasing energy expenditure or modulating lipid metabolism, 3) modulating fat stores or adipocyte differentiation, and 4) mimicking caloric restriction. Various novel drug candidates and targets directed against obesity are currently being explored. A few of them are also in the later phases of clinical trials. This review discusses the development of novel antiobesity drugs based on current understanding of energy homeostasis

show abstract

“…Several early clinical trials have been reported on the efficacy and safety of bremelanotide in males with ED, both as monotherapy and in combination with sildenafil. [45][46][47] Two Phase 1 safety studies of bremelanotide have been conducted in healthy volunteers. 45,46 One study provided bremenalotide subcutaneously, whereas the second used the intranasal formulation that has been chosen for further clinical development.…”

Section: Melanocortinsmentioning

confidence: 99%

“…[45][46][47] Two Phase 1 safety studies of bremelanotide have been conducted in healthy volunteers. 45,46 One study provided bremenalotide subcutaneously, whereas the second used the intranasal formulation that has been chosen for further clinical development. In both evaluations, erectile response was measured using the RigiScan device, without providing participants with additional sexual stimulation such as erotic videos.…”

Section: Melanocortinsmentioning

confidence: 99%

“…46 In this evaluation, men with ED had been successfully treated with sildenafil within the previous 6 months and were current users of sildenafil. Following a single intranasal dose of 4, 7, 10 or 20 mg of bremelanotide or matching placebo, subjects were monitored by RigiScan monitoring over a total of 145 min, beginning 30 min after dosing.…”

Section: Melanocortinsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical applications of centrally acting agents in male sexual dysfunction

Hellstrom

2008

Int J Impot Res

View full text Add to dashboard Cite

Currently available agents for erectile dysfunction (ED) share the same mechanism of action and pharmacologic properties. Therefore, they share the same limitations, including a principal focus on erection as an end-organ process. One of the relatively unexplored areas of research has been the potential for centrally acting agents to improve male sexual response. A variety of neurohormones and neurotransmitter systems are involved in the male sexual response, including testosterone, dopamine, serotonin and the melanocortin systems. Investigations to determine the utility of centrally acting agents as monotherapy or adjunctive therapy in men with ED or other forms of sexual dysfunction are underway. Bremelanotide, a melanocortin agonist, has been tested in men with ED and may prove to be one of the first centrally acting agents to have clinical utility in male sexual dysfunction.

show abstract

Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

Cited by 114 publications

References 22 publications

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra®

Obesity Pharmacotherapy: Current Perspectives and Future Directions

Clinical applications of centrally acting agents in male sexual dysfunction

Contact Info

Product

Resources

About